

RANDOMIZED PHASE III TRIAL OF MFOLFIRINOX +/- NIVOLUMAB VS. FOLFOX +/- NIVOLUMAB FOR FIRST-LINE TREATMENT OF METASTATIC HER2-NEGATIVE GASTROESOPHAGEAL ADENOCARCINOMA

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- HER2 negative unresectable or metastatic adenocarcinoma of esophagus, gastroesophageal junction, or stomach - have not received any prior treatment for this occurrence - prior neoadjuvant or adjuvant cytotoxic chemotherapy or adjuvant immunotherapy is allowed as long as it was completed at least 1 year ago - see link to clinicaltrials.gov for complete Inclusion criteria

Exclusion Criteria:

- women who are pregnant or breastfeeding - untreated, symptomatic brain metastasis - allogeneic tissue/organ transplant - see link to clinicaltrials.gov for complete Exclusion criteria

Conditions & Interventions

Conditions:

Cancer

Keywords:

Esophageal cancer, Gastric cancer

More Information

Description: This study compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.

Study Contact: Kristen Nelson - knelso65@fairview.org

Principal Investigator: Edward Greeno, M.D.

Phase: PHASE3

IRB Number: MMCORC061

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.